Fosun Pharma: Carcinoma, Non-Small-Cell Lung trials

The registry lists 18 Carcinoma, Non-Small-Cell Lung studies with Fosun Pharma as lead sponsor. 10 are open to participants now and 0 have results posted.

Phase 1 8Phase 2 10Phase 3 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingNCT07865910Phase 2/3
• Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid TumorsNot yet recruitingNCT07558200Phase 1
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLCRecruitingNCT07269782Phase 2
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung CancerRecruitingNCT07253142Phase 2
• A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT06907615Phase 2
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid TumorsRecruitingNCT06848699Phase 1/2
• A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung CancerNot yet recruitingNCT06847334Phase 3
• A Study of HLX42 in Advanced/Metastatic Solid TumorsRecruitingNCT06210815Phase 1
• A Phase Ib/II Clinical Trial to Evaluate the Safety and Efficacy of HLX208+HLX10 in NSCLC With BRAF V600E MutationRecruitingNCT05641493Phase 1/2
• A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) PatientsRecruitingNCT04237805Phase 1/2
• A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid TumorsActive, not recruitingNCT07160335Phase 1
• Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLCActive, not recruitingNCT06569420Phase 3
• A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC PatientsActive, not recruitingNCT05787613Phase 2
• HLX35(EGFR×4-1BB Bispecific) in Patients With Advanced or Metastatic Solid TumorsActive, not recruitingNCT05360381Phase 1
• HLX301 (TIGIT×PDL1 Bispecific) in Patients With Locally Advanced or Metastatic Solid TumorsStatus unknownNCT05102214Phase 1/2
• A Phase II Clinical Trial to Evaluate HLX208 in Advanced Non-small Cell Lung Cancer Patients With BRAF V600 MutationStatus unknownNCT05065398Phase 2
• A Randomized, Double-blind, Placebo Controlled Phase III Study to Investigate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy (Carboplatin-Nanoparticle Albumin Bound (Nab) Paclitaxel) in Patients With Stage IIIB/IIIC or IV NSCLCActive, not recruitingNCT04033354Phase 3
• A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT03952403Phase 3